

HR 9559

Innovative Technologies Impacted by COVID–19 Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 14, 2022

Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Dec 14, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/9559>

Sponsor

Name: Rep. Schneider, Bradley Scott [D-IL-10]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. DeGette, Diana [D-CO-1]	D · CO		Dec 14, 2022
Rep. Dunn, Neal P. [R-FL-2]	R · FL		Dec 14, 2022
Rep. LaHood, Darin [R-IL-18]	R · IL		Dec 14, 2022
Rep. Perlmutter, Ed [D-CO-7]	D · CO		Dec 14, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Dec 14, 2022
Ways and Means Committee	House	Referred To	Dec 14, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Dec 14, 2022)

Innovative Technologies Impacted by COVID-19 Act

This bill extends for one year certain Medicare pass-through payment adjustments for new drugs or biologics that would otherwise expire on December 31, 2022.

Actions Timeline

- **Dec 14, 2022:** Introduced in House
- **Dec 14, 2022:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.